AstraZeneca auctions off rights to another pipeline drug as Takeda grabs $400M Parkinson's deal
AstraZeneca has sold off marketing and development rights to another one of its pipeline assets.
This time it’s Takeda that’s stepping up, inking a deal …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
